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INTRODUCTION 
SCID is an inherited severe immunodeficiency of 
T-cell and B-cell functions that occurs in 
approximately 1: 50,000 live births. About 80% of 
affected patients are boys, and only approximately 
one third of patients with SCID have a positive 
family history. SCID may result from single X-
linked or autosomal recessive gene defects or, less 
commonly, from chromosome abnormalities (Table 
1). Peripheral T-cell dysfunction in all forms of 
SCID is mainly or entirely due to perturbed 
intrathymic maturation of αβ T cells (i.e., T cells 
that express αβ T-cell receptors [TCRs]) resulting 
in thymic hypoplasia.1 
The most common type is X-linked SCID, due 
to mutations in the gene encoding the common γ 
chain for multiple cytokine receptors; the second 
most common cause is adenosine deaminase  
 
 
deficiency (ADA deficiency), and the third most 
common cause is IL-7Rα–chain deficiency. In 25 
cases, the molecular defect remains unknown (those 
in the groups labeled autosomal recessive and 
unknown). No cases of CD45 deficiency have been 
seen at this institution.1 
Children who are diagnosed early and receive 
appropriate management and definitive treatment in 
the form of a hematopoietic stem-cell transplant 
(HSCT) have a far better prognosis than those 
children in whom the diagnosis has been delayed. 
Prenatal diagnosis is now available for those 
parents who have a positive family history. 
However, many children with SCID are born to 
parents with no family history of the disease. 
Children with SCID are healthy at birth and have no 
external characteristics of the condition. The 
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infectious complications which bring them to 
medical care may not initially be distinguishable 
from routine childhood infections, thus diagnosis 
may be delayed.5 
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Table 2. Rationale for newborn screening for SCID3 
 
Importance of early identification  
Establish diagnosis and institute immediate lifesaving treatment. 
Avoid inefficient, costly, dangerous ‘diagnostic Odyssey’. 
Provide families with genetic diagnosis and advice on reproductive risks. 
Learn incidence and true spectrum of SCID. 
Educate providers and public about SCID. 
Permit multicenter collaborative trials to determine optimal treatments. 
Barriers to early diagnosis without screening 
SCID and related conditions are rare. 
Infections are common in all infants, not just those with SCID. 
Over 80% of cases are sporadic, with no family history. 
Family history can be missed, or nonspecific. 
SCID infants are protected by maternal IgG for their first months of life. 
Because both a gene defect and environmental exposure are required for overt disease, presentation is variable. 
 
 
Table 3. Causes of lymphopenia4 
 
INFECTIOUS DISEASES  
AIDS  
Viral hepatitis  
Influenza  
Tuberculosis  
Typhoid fever  
Sepsis  
IATROGENIC  
Immunosuppressive therapy  
Corticosteroids  
High-dose PUVA therapy  
Cytotoxic chemotherapy  
Radiation  
Thoracic duct drainage  
INHERITED CAUSES  
Aplasia of lymphopoietic stem cells 
Severe combined immunodeficiency associated 
with defect in IL-2 receptor γ-chain,    
deficiency of ADA or PNP, or unknown  
Ataxia-telangiectasia  
-Wiskott-Aldrich syndrome  
Immunodeficiency with thymoma 
Cartilage-hair hypoplasia  
 Idiopathic CD4 T lymphopenia  
SYSTEMIC AND OTHER DISEASES  
Dietary deficiency  
Systemic lupus erythematosus   
Myasthenia gravis  
Hodgkin disease  
Protein-losing enteropathy   
Renal failure  
Sarcoidosis  
Thermal injury  
Aplastic anemia 
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Early recognition of SCID should be 
considered a pediatric emergency6 because a 
diagnosis before live vaccines or non-irradiated 
blood products are given and before the 
development of infections permits lifesaving 
unfractionated HLA-identical or T cell depleted 
haploidentical nonablative hematopoietic stem cell 
transplantation,7 enzyme replacement therapy,8 or 
gene therapy.9 However, unlike infants with 
DiGeorge syndrome, most infants with SCID 
appear physically normal at birth until they begin to 
develop infections, where failure to thrive begins. 
In most cases there is no family history of SCID.5 
The Incidence of disseminated BCG disease 
ranged from 0.06 to 3.4 cases per million 
vaccination, and the mortality rates remained high 
in immunocompromised patients (60-38%).10 The 
disseminated BCG infection may be the first 
presentation prior to the diagnosis of 
immunodeficiency.11 The most common symptoms 
of disseminated BCG infection died even when they 
were aggressively managed.12 SCID is not apparent 
at birth and early recognition is essential for life 
saving treatment, hence SCID has been recognized 
as a candidate for newborn screening for many 
years.13 
All children with SCID are lymphopenic at 
birth14, thus routine blood counts with manual 
differentials could diagnose nearly all cases of 
SCID at birth.15 However there are a high number of 
both false-positives and -negatives, as not all 
children who are lymphopenic have SCID and some 
patients with SCID may have a low-normal 
absolute lymphocyte count because of the presence 
of B cells (IL2RG, JAK3 and IL7R gene defects) or 
maternal lymphocytes. Furthermore this test is 
potentially labor-intensive since it does not make 
use of the dried blood spots (DBS) collected 
routinely from all neonates at birth in the USA. The 
UK Primary Immunodeficiency Network also uses 
a low lymphocyte count as an entry into their 
protocol for screening for SCID. However a recent 
audit from Birmingham, UK, found that although 
only 1 out of the 56 cases of lymphopenia was 
documented by the clinician, there were no clear 
missed cases of SCID. They therefore thought it 
would be more cost-effective to discuss cases of 
lymphopenia with an immunologist before doing 
further investigations for SCID.16 Direct detection 
of gene mutations using re-sequencing microarray 
chips is also an option. Although this potentially 
will have a high number of false-negatives, it would 




Study Population  
This cross sectional study comprised 500 newborn 
infants delivered either vaginally or by caesarean 
section at the Obstetrics and Gynecology Hospital, 
Ain Shams University, Cairo, Egypt. All newborns 
were included in the study with no exclusion 
criteria. They were 248 males and 252 females. 
Their gestational ages ranged from 27 – 42 weeks 
(mean 37±2.6 wks). Their weight ranged from 0.8- 
5 Kg (mean 3.0±0.6 kg). Out of the 500 neonates, 
only 3 had congenital malformations, while 8 had 
family history of unexplained sib death. Out of the 
500 neonates, 264 were delivered vaginally, while 
236 were delivered by caesarean section. Premature 
rupture of membrane was reported in 84 cases. An 
informed consent was obtained from the parents or 
care givers of all children before enrollment. The 
study protocol was approved by the ethics 
committee of the Pediatric Department, Ain Shams 
University.  
 
Study Measurements  
Prenatal history was taken from the mother for 
medical history, fever, chorioamnionitis and pre-
mature rupture of membrane >18 hrs. Also family 
history of previously diagnosed PID sibling or 
previous death whether due to infections or due to 
an unknown cause was traced.  
Apgar scores were plotted for all neonates at 
one and 5 minutes. All neonates were subjected to 
general and systemic clinical examination. 
Two ml of cord blood (during time of delivery) 
were collected from each infant under complete 
aseptic condition and put in a vacuette tube 
containing ethylene diamine tetra acetic acid 
(EDTA) (1.2 multigravida/ml). CBC was performed 
using coulter counter (Beckman instrumentation) 
including the red blood cells (RBCs) hemoglobin 
(HB) hematocrit (HCT), mean corpuscular volume 
(MCV), mean corpuscular hemoglobin (MCH), 
mean corpuscular hemoglobin concentration 
(MCHC), WBC and platelets. Manual differential 
was done. 
• Absolute lymphopenia was considered in any cord 
blood sample if lymphocytic count was less than 
2500/mm3.18 
• Parents of lymphopenic newborn infants were told 
not to give their newborns live attenuated 
vaccines before doing further investigations. 
• Only the lymphopenic newborn infants were 
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Statistical methods: 
The collected data were coded, tabulated, and 
statistically analyzed using SPSS program 
(Statistical Package for Social Sciences) software 
version 18.0. 
Inferential analyses were done for normally 
distributed quantitative variables using independent 
t-test in cases of two independent groups. 
Inferential analyses were done for qualitative data 
using Chi square test for independent variables. 
Correlations were done using Pearson correlation 
for numerical parametric data. The level of 
significance was taken at p value <0.050. 
 
RESULTS 
In the present study, absolute lymphopenia was 
found in 8 (1.6%) neonates at delivery while 492 
(98.4%) of them had absolute lymphocytic count 
above 2.5×103/cmm. All lymphopenic patients were 
followed up and advised not to administer BCG 
vaccine. Another CBC and ALC were done after 
one month. All of them proved to have normal ALC 
in the second evaluation after one month.  
Analysis of ALC among our patients with 
normal ALC revealed that, 45 (9%) of our neonates 
had ALC ≥ 7.5×103/cmm, 43 (8.6%) had ALC of 
6.5-7.5×103/cmm, 65 (13%) had ALC of 5.5-
6.5×103/cmm, 129 (25.8%) had ALC of 4.5-
5.5×103/cmm, 141 (28.2%) had ALC of 3.5-
4.5×103/cmm and finally 69 (13.8%) had an ALC of 
2.5-3.5×103/cmm.  
Among our study population 222 (44.4%) were 
primigravida and 278 (55.6%) were multigravida. 
Also, 84 (16.8%) experienced pre-mature rupture of 
membrane while maternal diseases were reported in 
89 (17.8%) of our mothers.  
Three neonates (0.6%) had congenital 
anomalies, one (0.2%) had dysmorphic features and 
8 (1.6%) had family history of unexplained death. 
The gestational age, weight and Apgar score at 
1 and 5 minutes were significantly lower in 
neonates with lymphopenia (p = <0.001, 0.031, 
<0.001 and <0.001 respectively). Also our neonates 
with lymphopenia showed female predominance, 
M/F ratio was 1:7 in comparison to 247: 245 in the 
group with normal ALC (p = 0.034).  
There was no significant difference between 
those with and those without lymphopenia as 
regards maternal age, gravida, mode of delivery, 
pre-mature rupture of membranes  presence of 
maternal diseases and maternal drug intake (p = 
0.35, 0.69, 0.87, 0.74 ,0.42 and 0.06  respectively).  
Moreover, the presence of congenital 
anomalies, dysmorphic features or relevant family 
history of unexplained death did not vary 
significantly among those with and those without 
lymphopenia.  
According to our study, a significant positive 
correlation was found between ALC and maternal 
age, TLC and HCT (p = 0.003, <0.001 and 0.031 
respectively). Also a significant negative 
correlation was found between ALC and gestational 
age MCH and MCHC (p = 0.013, 0.003 and <0.001 
respectively). ALC did not vary significantly in 
relation to Apgar scores at one and 5 minutes (p = 
0.179). 
Studying the combined effect of (child death, 
pre-mature rupture of membrane  gestational age  
weight, sex, maternal disease, maternal drugs, 
delivery mode and maternal age) showed a 
significant correlation with ALC. Neonatal sex and 
weight bore a significant positive correlation with 
ALC in the presence of other variables  (p = 0.000 
and 0.003 respectively).   
 
 
Table 4. Comparison of some data between patients with and without lymphopenia in the current study. 
 




Gestational age (wk) 34.3 + 3.8 37.9 + 2.6 0.001  
Weight (kg) 2.1 + 1.0 3.1 + 0.6 0.031  
APGAR (1 min) 4.4 + 1.0 5.4 + 0.9 0.001  










CI: confidence interval; OR: odds ratio 
 
 
Neonatal screening for lymphopenia 
  79
 




Mutations in 13 different genes have been found to 
cause SCID, which is uniformly fatal in the first 
two years of life.19 Disseminated BCG disease is 
one of the most common causes of death in patients 
with primary immunodeficiency diseases, 
particularly SCID.20 Taking an exact family history 
before vaccination is strongly recommended, as 
families with low socioeconomic status may not 
provide information if not asked.21 
With this as a background we were stimulated 
to evaluate the incidence of neonatal lymphopenia 
at birth as an entry to a screening program for SCID 
as all children with SCID are lymphopenic at 
birth.14 Thus, routine blood counts with manual 
differentials could diagnose nearly all cases of 
SCID at birth.15 
Our study was performed on 500 neonates. The 
frequency of lymphopenia (ALC< 2.5 × 103) in the 
study group was (1.6%). One patient was male 
(12.5%) and 7 were females (87.5%). Thus 
lymphopenia was more frequent in females than 
males. 
Concerning the ranges of lymphocyte counts in 
the study group, 1.6% were (1.5-<2.5×103), 13.8% 
were (2.5-<3.5×103), 28.2% were (3.5-<4.5×103), 
25.8% were (4.5-<5.5×103), 13% were (5.5-
<6.5×103), 8.6% were (6.6-<7.5×103) and 9% were 
≥ 7.5×103/mm3. More than half of the cases (54%) 
had a lymphocytic count in the range of (3.5-
<5.5×103/mm3). 
Because most infants with SCID lack T cells, 
the absolute lymphocyte count (ALC) could be used 
as a screening test for this syndrome. T cells 
comprise 70% of circulating lymphocytes in 
healthy human subjects throughout life. Therefore 
lymphopenia will be present in nearly all infants 
with SCID from the time of birth as a result of their 
missing 70% of circulating lymphocytes. However, 
many infants do not have blood counts performed. 
Additionally, many physicians are not aware of the 
usefulness of the ALC, even though they are taught 
throughout medical school about the importance of 
the absolute neutrophil count.22 
Work by Dr. Rebecca Buckley at Duke 
University compared lymphocyte levels between 
normal and SCID babies at birth has shown that 
most SCID patients had low absolute lymphocyte 
counts at birth (range of absolute lymphocyte 
counts was 114–2210 lymphocytes/mm3 for 25 
SCID newborns and 1670–8910 lymphocytes/mm3 
for 14 normal infants at birth Patients with SCID 
often had numerous prior blood counts clearly 
showing lymphopenia, but the physicians caring for 
the infants did not appreciate the significance of 
this.22 However, there is a high number of both false 
positive and negative results, as not all children 
who are lymphopenic have SCID and some patients 
with SCID may have a low normal absolute 
lymphocytic count because of the presence of B 
cells (IL2RG, JAK3 and IL7R gene defects) or 
maternal lymphocytes.23 
The longest pilot study (44 months) was 
conducted in Wisconsin24 and has reportedly 
discovered 4 cases of SCID and 7 cases of T-cell 
lymphopenia that were not related to SCID of a 
total of 243,707 newborns screened. The initial 
results of screening for one year have been 
published.25 The discovered cases had undergone 
either hematopoietic stem cell transplantation or 
enzyme replacement therapy and are surviving. 
Massachusetts was the second state to initiate a 
pilot study24  and has  screened for 31 months, 
during which time it has reportedly discovered one 
case of SCID and 14 cases of T-cell lymphopenia 
that were not related to SCID of a total of 161,707 
newborns screened.26 The infant with SCID had 
undergone transplantation and is surviving.27 
New York followed a screening program24 for 
a total of 136,635 newborns over 11 months and 
has reportedly discovered 4 cases of SCID and 12 
cases of T-cell lymphopenia that were not related to 
SCID. All 4 patients with SCID have been treated 
appropriately and are surviving. 
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California has been screening for 13 months 
and has reportedly24 discovered 5 cases of SCID, 6 
cases of variant SCID, and 3 cases of T-cell 
lymphopenia that was not related to SCID of a total 
of 358,000 newborns screened. All of the infants 
with SCID have received appropriate therapy and 
are surviving.  
The three pilot studies of  Puerto Rico, 
Louisiana, and the Navajo Nation have reportedly 
not yet discovered any cases of SCID and only 4 
cases of T-cell lymphopenia that were not related to 
SCID of an aggregate total of just over 60,000 
newborns screened. Thus far, newborn screening 
for SCID with the TREC assay appears to be 100% 
sensitive because no other cases of SCID have been 
discovered in the states performing the pilot studies 
during the time period that the screening has been 
conducted. However, it is apparent that many other 
conditions with T-cell lymphopenia that need 
medical attention are being detected by using this 
screening method. For the 40 patients without SCID 
detected in aggregate, approximately 30% had 
DiGeorge syndrome, 35% had idiopathic T-cell 
lymphopenia and are being followed closely, 5% 
had trisomy 21, and 30% had T-cell lymphopenia 
associated with other genetic diseases or 
conditions.24 
 Neonates with lymphopenia were comparable 
to those with normal lymphocyte counts in terms of 
variables related to maternal history namely age, 
gravida, pre-mature rupture of membranes maternal 
diseases and drug history. Similarly, the presence of 
congenital diseases, dysmorphic features and 
history of unexplained sib death did not 
significantly vary among both groups. This can be 
attributed to the fact that lymphopenia was transient 
as evident from the second blood sample. 
Weight, gestational age  and Apgar score at 1 
and 5 minutes were significantly lower in cases 
with lymphopenia  than cases without lymphopenia  
with female predominance in the lymphopenia 
group; a finding which can suggest that this 
transient lymphopenia could be related to transient 
neonatal infections. 
A significant positive correlation was found 
between (maternal age, WBC, HCT) and ALC. 
Moreover, no significant correlation between 
APGAR score 1and 5 and ALC could be plotted, a 
finding which might be due to the small sample 
size. 
Neonatal sex and weight bore a significant 
positive correlation with ALC in the presence of 
other variables namely previous child death, pre-
mature rupture of membranes,  gestational age, 
weight, sex, maternal diseases and drugs, delivery 
mode and maternal age (p=0.000 and 0.003 
respectively); finding which can suggest the 
multifactorial impact on absolute lymphocytic 
count. 
In conclusion, lymphopenia is not an 
uncommon finding among neonates at screening 
and is noted to be associated with a lower Apgar 
score.  We recommend introduction of a neonatal 
absolute lymphocytic count evaluation as a part of 
neonatal screening program for pre-symptomatic 
detection and early intervention for neonates with 
SCID. Also, BCG vaccine and other live attenuated 
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